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We assessed neurologic sequelae associated with an 
enterovirus 71 (EV71) outbreak in South Korea during 2009. 
Four of 94 patients had high signal intensities at brainstem 
or cerebellum on magnetic resonance imaging. Two patients 
died of cardiopulmonary collapse; 2 had severe neurolog-
ic sequelae. Severity and case-fatality rates may differ by 
EV71 genotype or subgenotype.
S
everal major outbreaks of enterovirus 71 (EV71) have 
been reported since 1974 (1,2). Countries of the Asian 
Pacific  Rim  particularly  have  been  recently  affected  by 
large outbreaks of EV71-associated hand-foot-and-mouth 
disease (HFMD). Most patients with HFMD experience 
a mild disease course, but recent reports on the outbreak 
of EV71 infection in various countries, including Taiwan, 
People’s Republic of China, and Malaysia, indicate that 
some EV71-infected persons have severe neurologic com-
plications or systemic disease (3,4).
The varying prevalences of neurologic complications 
of EV71 infection among outbreaks are assumed to have 
been driven by differences of genotypes and co-infection 
with other viruses, such as a newly characterized adenovi-
rus; however, the exact reasons remain unclear (3,5,6). We 
report an outbreak of EV71 infection with neurologic in-
volvement on the basis of information from a prospective, 
clinical,  and  virologic  study  that  was  collected  through 
South Korea’s nationwide surveillance system.
The Study
The EV surveillance system in South Korea consists of 
62 clinics (8 primary clinics, 14 secondary hospitals, and 40 
tertiary hospitals located nationwide) managed by pediatric 
physicians (Figure). During 2009, a total of 2,427 cases of 
viral disease were reported to the Korea Centers for Dis-
ease Control and Prevention through a web-based system. 
In addition, an experienced neurologist (W.-S.R.) collected 
detailed clinical information about, and results of imaging 
studies of, patients reported to have central nervous system 
(CNS) involvement. We monitored the patients until they 
were discharged or for 3 weeks if duration of hospitaliza-
tion was >3 weeks. Patient outcome was classified into 1 
of 4 groups; no sequelae (neurologic dysfunction without 
dependency), mild sequelae, severe sequelae (neurologic 
dysfunction requiring assistance), or death.
EV  genome  detection  was  attempted  by  real-time 
reverse  transcription–PCR  (RT-PCR)  by  using  TaqMan 
technology (Applied Biosystems, Foster City, CA, USA). 
Briefly, viral RNAs were extracted by using the magnetic 
bead–based  viral  nucleic  acid  purification  protocol  de-
scribed by Boom et al. (7). Subsequently, 1-step real-time 
RT-PCR was performed by using a dual-labeled fluoro-
genic EV-specific probe and primers designed on the basis 
of previous data (8). For genotyping, seminested RT-PCR 
was used to amplify part of the viral protein (VP) 1 gene 
of EV, based on the Korea Centers for Disease Control and 
Prevention protocol for detection of pan-EV, and sequenc-
ing analysis for VP1 amplicon was performed by using au-
tomatic sequencer and DNAstar software package (9).
In 2009, a total of 2,427 patients were recruited. Of 
these patients, 519 had symptoms of HFMD or herpangina. 
EV was detected in 461 (19%) of all patients and in 321 
(66%) of patients with suspected HFMD and herpangina. 
Samples from 331 (72%) of the 461 EV-seropositive pa-
tients were available for genotyping (Table 1). In addition, 
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Figure. Geographic distribution of clinics participating in enterovirus 
surveillance, South Korea, 2009.Enterovirus 71 with CNS Involvement
we found 112 cases of HFMD with CNS complications 
(meningitis or encephalitis); EV was detected in 95 (85%) 
and EV71 in 92 (82%) case-patients. Furthermore, EV71 
was detected in 2 of the 187 case-patients in which menin-
gitis without HFMD or herpangina was diagnosed. Thus, 
94 patients were enrolled in this study. The incidence of 
EV71 infection peaked in July and decreased drastically in 
August.
Fifty-nine (63%) patients were boys. Mean (SD) pa-
tient age was 46 (29) months (range 1 month–12 years); 
12 (13%) patients were <1 year of age. Initial diagnoses 
were viral meningitis (60 patients), encephalitis (20), acute 
cerebellar ataxia (12), acute transverse myelitis (1), and 
Guillain-Barré syndrome (1). Rash and fever were the most 
common initial symptoms (85% and 81%, respectively). 
Approximately 50% of patients had headache, vomiting, 
and neck stiffness. Cerebrospinal fluid (CSF) profile was 
available for 77 patients. Median leukocyte count was 111 
cells/mm3  (interquartile  range  48–318  cells/mm3),  mean 
(SD) protein level was 43 (18) mg/dL, and mean (SD) glu-
cose level was 69 (13) mg/dL. Of the 32 (34%) patients 
who underwent magnetic resonance imaging of the brain, 
24 (75%) had normal results, 4 (13%) had meningeal en-
hancement  on  T1-enhanced  imaging,  and  4  (13%)  had 
high signal intensity at the brainstem or cerebellum on T2-
weighted or fluid-attenuated inversion recovery imaging. 
All brain parenchymal lesions were located in the brain-
stem or cerebellum, and the 4 patients with brain lesions 
subsequently experienced ataxia.
EV71 was found in 72 (92%) of 78 lower gastrointes-
tinal tract samples, 37 (60%) of 62 upper respiratory tract 
samples, and 2 (5%) of 37 CSF samples. On the basis of 
sequence analysis, C4a, with high similarity to strains from 
China in 2008, was a dominant serotype of EV71 (76%); 
and C1 was found in 2 patients and C5 in 1 patient.
The results of this and previous studies are summarized 
in Table 2. The partial VP1 sequences of Korean EV71 
strains were registered in GenBank (HM443164–644), and 
viral genetic identity belonged to C4a genotype, which was 
not a prevailing genotype in the previous reports of other 
Asian Pacific countries.
Conclusions
The severity of, and case-fatality rate for, EV71 infec-
tion in our population were relatively low compared with 
those of previous reports in which the case-fatality rate 
ranged from 10% to 26% (12). This discrepancy has some 
plausible explanations. In previous studies, the prevailing 
genotype of EV71 was B (1,14). In contrast, the predom-
inant genotype in our patients was C4, particularly C4a, 
which has been prevalent in China since 2008 (11). The 
case-fatality rate also was low in China, with 3 patients dy-
ing of the 1,149 reported with EV71 infection (11). There-
fore, the virulence of the C4a genotype may be milder than 
that of other genotypes.
We detected EV71 rarely in the CSF of our patients. 
Possible explanations include the transient presence of the 
virus in CSF, a lower viral load in CSF, and use of an EV 
PCR assay that had not been optimized to detect EV71. 
In our population, the CSF profile of EV71 infection ap-
peared to be broadly similar to that of other cases of vi-
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Table 1. Genotype distribution of enteroviruses, South Korea 
Genotype No. cases (%)
CA2 24 (7.3)
CA5 35 (10.6)
CA6 32 (9.7)
CA12 3 (0.9)
CA16 29 (8.8)
CB1 8 (2.4)
E3 8 (2.4)
E6 3 (0.9)
E9 2 (0.6)
E11 8 (2.4)
E30 2 (0.6)
E33 3 (0.9)
E71 174 (52.6)
Total 331
Table 2. Enterovirus 71 outbreaks, Asia* 
Reference  Outbreak location, year
HFMD Complicated HFMD
Genotypes 
detected
GenBank
accession nos.
No.
patients
No. patients 
with EV71 
No.
patients
No. patients 
with EV71
Zhang et al. (10) Fuyang, PRC, 2008 151 59 112 42 C4a EU703812–14, 
GQ121417–41
Zhang et al. (11) Shandong, PRC, 2007 105 55 11 6 C4a EU753365–417
AbuBakar et al. (1) Brunei, 2006 >100 34 NA NA B4, B5 FM201328–61
Ooi et al. (12) Sarawak, 
Malaysia, 2000–2004
773 277 102 56 B4, C1, B5 AY905549–50, 
AY794036, 
AF376069
Lin et al. (13) Taiwan, 1998 NA NA 405 78 C2 AY055194–97, 
FJ357343
This study South Korea, 2009 519 168 112 92 C4a, C1, 
C5
HM443164–644
*HFMD, hand-foot-and-mouth disease; EV71, enterovirus 71; PRC, People’s Republic of China; NA, not available. ral encephalitis or meningitis. Thus, analyzing the CSF 
of patients with suspected EV71 infection may provide 
minimal information.
Several studies have shown that EV71 infection rate 
was most common during the warmer season (15). In our 
study,  the  seasonality  of  EV71  infection  initially  was 
similar to that of previous reports. However, the preva-
lence of EV71 infection decreased drastically in August, 
the warmest month in South Korea. A possible reason for 
this difference could be that in 2009, influenza pandemic 
(H1N1) 2009 affected South Korea; with the first death 
caused by it in South Korea reported in August. As a con-
sequence, personal hygiene practices, such as handwash-
ing and covering one’s cough or sneeze, were emphasized 
to  prevent  virus  spread.  Considering  the  transmission 
route of EV71 infection, the emphasis on personal hy-
giene may thus have hindered the spread of EV71, as well 
as of the influenza virus.
We report 94 cases of PCR-confirmed EV71 infection 
with CNS involvement, including 2 deaths, and provide ad-
ditional clinical and virologic information about EV71. We 
confirmed that EV71 commonly involved the brainstem 
and cerebellum, and therefore ataxia is not uncommon in 
EV71 infection with CNS involvement. In addition, our 
study supports the hypothesis that the severity of and case-
fatality rates for EV71 infection may differ by genotype or 
subgenotype of EV71.
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